10-Q quarterly report · filed Nov 3, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 10-Q Quarterly Report

Short answer

Mirum Pharmaceuticals, Inc. (MIRM) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $186M (up 39.6% year over year) with net income of −$41M.

Q3 2026 key financials · XBRL

Revenue
$186M
+39.6% YoY · +5.4% QoQ
Net income
−$41M
−1503.3% YoY · +39.4% QoQ
Operating margin
-32.2%
EPS (diluted)
−$0.32
−557.1% YoY · +46.7% QoQ

Source: XBRL data from the Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 10-Q on SEC EDGAR. USD.

Mirum Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $185.7M, up $52.7M YoY from $133.0M
  • Net loss $40.8M vs $2.9M net income; operating margin -32.2% vs 2.0%
  • Best performer Livmarli: $133.4M, up $41.2M; Bile Acid Medicines $52.3M, up $11.5M
  • Cash, equivalents and investments $500.5M vs $391.4M at December 31, 2025; nine-month operating cash flow -$277.3M
  • Outlook: cash sufficient through at least next 12 months; continued net losses and higher brelovitug development spending expected

Risk Factors

  • New regulatory risk: July 2026 FDA Form 483 cited untimely expedited adverse-event reports by Mirum and its pharmacovigilance vendor
  • Most material update: FDA recommended a Phase 3 volixibat PSC study, delaying the planned NDA submission based on VISTAS data
  • Market-access risk: Medicare negotiation, Most-Favored-Nation pricing proposals and German orphan-drug threshold reduction to €30 million
  • Competitive risk: LIVMARLI generic ANDA filings triggered four 2025 patent complaints and a 2026 tablet litigation
  • Financial risk: nine-month 2026 net loss $898.1 million, accumulated deficit $1.6 billion as continued losses are expected

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Mirum Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.